Autopsy report · NCT03720717

Baclofen as a Perioperative Analgesic Adjuvant

“Futility analysis at midpoint analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years before it started.
• Ran for about 2 years before it stopped.
• 34 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

University of Alabama at Birmingham

Sponsor type

University, hospital or other

Conditions

Pain

Interventions

Baclofen 10mg; Placebo

Participants

34

Sites

1

Countries

United States

Trials that died the same way

• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
  “Interim futility analysis” (71% match in meaning)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
  “Based on interim analyses for futility” (71% match in meaning)
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (68% match in meaning)
• Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
  “Assessment for futility” (65% match in meaning)
• Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
  “Study futility based on the interim analysis” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.